A Role for Genetics in Racial Disparities of Therapy-Related Cardiomyopathy.
A Role for Genetics in Racial Disparities of Therapy-Related Cardiomyopathy.
复制标题
遗传学在治疗相关心肌病种族差异中的作用。
DOI：
10.1158/0008-5472.can-21-0137
复制
发表时间：
2021
期刊：
影响因子：
11.2
通讯作者：
Richard,MelissaA
中科院分区：
文献类型：
--
作者：
Brown,AustinL;Richard,MelissaA
心肌病是儿童癌症幸存者发病率和早期死亡率的重要来源，并可能对少数群体造成不成比例的影响。然而，在种族和民族多元化的幸存者群体中评估这些结果的研究很少。Sapkota和他的同事的一项研究系统地表征了基于遗传祖先的与治疗相关的心肌病发病率的差异，并调查了导致这种不平等的基因变异。值得注意的发现包括非裔美国人儿童癌症幸存者患心肌病的风险不成比例，以及发现遗传基因变异，这可能会增加这些人患心肌病的易感性。尽管需要更大规模的研究来证实这些发现，但将这一知识纳入临床风险描述可能有助于将注意力集中在那些特别容易受到心血管不良后果影响并最有可能从预防策略中受益的患者群体上。
Cardiomyopathy is a significant source of morbidity and early mortality among survivors of childhood cancer, and may disproportionately affect minorities. However, there have been few studies evaluating these outcomes among racially and ethnically diverse survivor populations. A study by Sapkota and colleagues systematically characterizes disparities in the incidence of treatment-associated cardiomyopathy on the basis of genetic ancestry and investigates genetic variants responsible for this inequality. The noteworthy findings include a disproportionate risk of cardiomyopathy among African-American childhood cancer survivors and the identification of inherited genetic variants, which may confer increased susceptibility to cardiomyopathy among these individuals. Although larger studies are needed to confirm these findings, incorporating this knowledge into clinical risk profiles may help focus attention on patient populations who are particularly vulnerable to adverse cardiovascular outcomes and most likely to benefit from preventive strategies.See related article by Sapkota et al., p. 2556